Cancer News

The latest in diagnostics and treatment

As a practice dedicated to the constant exploration of effective treatment for cancer, VCI aims to be your source for news on the latest breakthroughs. Please keep this page as a bookmark and check back regularly. Because one of the most important aspects of fighting cancer is knowing all you can.

World Cancer News

Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients (08/16/2017)

Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center. The findings were reported online by the Journal of the …

Continue reading "Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients"

Head and Neck Cancer-What You Need to Know (08/14/2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck cancers account for about 3 percent of …

Continue reading "Head and Neck Cancer-What You Need to Know"

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia (08/10/2017)

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the Real Time IDH2 Assay, which is used to detect specific mutations in the IDH2 …

Continue reading "FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia"

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma (08/09/2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. The Breakthrough Therapy Designation …

Continue reading "Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma"

Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers (08/08/2017)

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy. Patient-derived orthotopic xenografts (PDOX) are unique models where a patient’s individual tumor is grown in …

Continue reading "Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers"

FDA Approves Vyxeos for Adults with Poor Prognosis AML (08/07/2017)

The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC. Approval …

Continue reading "FDA Approves Vyxeos for Adults with Poor Prognosis AML"

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers (08/02/2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) is a nationwide trial to explore whether targeted therapies can be effective for children and adolescents with solid tumors that …

Continue reading "Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers"

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence (08/01/2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-center …

Continue reading "Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence"

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (07/26/2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research …

Continue reading "Balance and Gait is Negatively Impacted By Chemotherapy Treatment"

Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy (07/25/2017)

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell Acute Lymphoblastic Leukemia.  CAR-T also shows promise in ALL, CLL, other B-cell malignancies, and other cancers. In CAR T-cell therapy, a patents immune systems T-cells are collected and reprogrammed in the laboratory to recognize and …

Continue reading "Chimeric Antigen Receptor (CAR) T-cell Immunotherapy – Crafting a Better T Cell for Immunotherapy"